A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis.
Tomoya SanoKeisuke AmanoTatsuya IdeKeiji YokoyamaKazunori NoguchiHiroki NakamuraHiroshi IsodaMiki OhnoMiki ShirachiYasuyo MoritaYoichi YanoShuji SumieToshihiro KawaguchiReiichiro KuwaharaTeruko Arinaga-HinoHirokazu TakahashiSatoshi ShakadoFumihito HiraiTakumi KawaguchiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Sofosbuvir/velpatasvir treatment improved the liver functional reserve in patients with hepatitis C virus-related decompensated cirrhosis at 24 weeks post-treatment. However, BMI ≥25 inhibited improvement in CP class. Additionally, decision tree analysis revealed that a combination of hepatic encephalopathy, serum sodium levels, and BMI were diversity profiles associated with no improvement in liver functional reserve after the treatment.